ASC2ESCALATE: Asciminib Monotherapy as First or Second Line Treatment
Condition: Chronic Myelogenous Leukemia
Sponsor: Novartis Pharmaceuticals
Full Title
Protocol CABL001AUS08: A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia
Study Treatment
Oral Asciminib
Eligibility/Info
- Chronic phase CML
-First or second line therapy
- No known T315I mutation
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
